Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor

Oliver Sartor MD Advisory Board

See All Experts

featured

Published in Oncology

Journal Scan / Research · March 22, 2018

Durvalumab as Third-Line or Later Treatment for Advanced Non–Small Cell Lung Cancer

The Lancet Oncology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Durvalumab as Late Stage Treatment of NSCLC: Relationship With EGFR, ALK and PD-L1 Positivity—A West Cancer Center Perspective

The Lancet Oncology

Durvalumab as Third-Line or Later Treatment for Advanced Non-Small-Cell Lung Cancer (ATLANTIC): An Open-Label, Single-Arm, Phase 2 Study

Lancet Oncol 2018 Mar 12;[EPub Ahead of Print], MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, J Corral Jaime, JE Gray, J Powderly, C Chouaid, P Bidoli, P Wheatley-Price, K Park, RA Soo, Y Huang, C Wadsworth, PA Dennis, NA Rizvi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Durvalumab as Third-Line or Later Treatment for Advanced Non–Small Cell Lung Cancer

Additional Info

Durvalumab as Third-Line or Later Treatment for Advanced Non-Small-Cell Lung Cancer (ATLANTIC): An Open-Label, Single-Arm, Phase 2 Study

Further Reading

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Ponsegromab for Treating Cancer Cachexia

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Recently Updated